Enabling Tomorrow's Breakthroughs Today

Our Services

We focus on indication selection and asset value maximisation

We assess your assets and goals to shape a focused indication strategy—leveraging advanced technology and expert networks to accelerate value, de-risk drug development, and expand impact.

Indication Strategy

Indication Strategy

Empowering Life Sciences leaders

Empowering Life Sciences leaders

For Life Sciences leaders and investors, we craft clear, strategic insight to unlock value, de-risk development, and accelerate smart growth ensuring every decision is grounded in data, opportunity, and impact.

We deliver real-world evidence-based indication prioritization that sharpens focus and streamlines decision-making across the portfolio.

We deliver high-impact strategies in weeks—validating known science, uncovering opportunities, and securing key milestones.

Biotech, Pharma, & Financial Sponsors

Buy-, Sell-Side Advisory

Buy-, Sell-Side Advisory

Informed by our Indication Strategy

Informed by our Indication Strategy

Guided by our Indication Strategy, we turn complexity into clarity. From asset sales to co-development, we align interests, manage risk, and deliver data-driven insights that empower unbiased, confident decisions.

True partnership, real alignment – We work as an extension of your team, ensuring every recommendation supports your goals.

Decisions backed by data and experts in the field – No guesswork. Actionable insights that drive smarter, faster, patentable outcomes.

Any deal size & type

Our Process

Turning real-word data into real-world impact

Discover how we create measurable success in Life Sciences programs.

01

Define the Right Data and Biological Anchors

We begin by sourcing high-quality real-world data (RWD) and identifying relevant patient cohorts. In parallel, we define key biological anchors based on the asset’s mechanism of action—guiding our exploration of disease relevance through phenotypic similarity, knowledge graphs, and omics data.

01

Define the Right Data and Biological Anchors

We begin by sourcing high-quality real-world data (RWD) and identifying relevant patient cohorts. In parallel, we define key biological anchors based on the asset’s mechanism of action—guiding our exploration of disease relevance through phenotypic similarity, knowledge graphs, and omics data.

01

Define the Right Data and Biological Anchors

We begin by sourcing high-quality real-world data (RWD) and identifying relevant patient cohorts. In parallel, we define key biological anchors based on the asset’s mechanism of action—guiding our exploration of disease relevance through phenotypic similarity, knowledge graphs, and omics data.

02

Discover and Score Indication Opportunities

Using AI-driven analytics, we generate and rank potential indications. Each is evaluated across scientific, clinical, and commercial dimensions—factoring in unmet need, feasibility, and strategic fit—validated through literature, expert input, and proprietary scoring models.

02

Discover and Score Indication Opportunities

Using AI-driven analytics, we generate and rank potential indications. Each is evaluated across scientific, clinical, and commercial dimensions—factoring in unmet need, feasibility, and strategic fit—validated through literature, expert input, and proprietary scoring models.

02

Discover and Score Indication Opportunities

Using AI-driven analytics, we generate and rank potential indications. Each is evaluated across scientific, clinical, and commercial dimensions—factoring in unmet need, feasibility, and strategic fit—validated through literature, expert input, and proprietary scoring models.

03

Deliver Data-Driven Recommendations

We develop detailed indication scorecards and a ranked opportunity list, tailored to your asset’s profile. These strategic outputs inform lifecycle planning, prioritization, and internal or external development options.

03

Deliver Data-Driven Recommendations

We develop detailed indication scorecards and a ranked opportunity list, tailored to your asset’s profile. These strategic outputs inform lifecycle planning, prioritization, and internal or external development options.

03

Deliver Data-Driven Recommendations

We develop detailed indication scorecards and a ranked opportunity list, tailored to your asset’s profile. These strategic outputs inform lifecycle planning, prioritization, and internal or external development options.

04

Execute on Strategy: Monetize or Advance

Beyond analysis, we support execution—providing buy- or sell-side advisory to help you monetize the asset or advance it through partnerships, co-development, or internal investment—maximizing strategic and financial return.

04

Execute on Strategy: Monetize or Advance

Beyond analysis, we support execution—providing buy- or sell-side advisory to help you monetize the asset or advance it through partnerships, co-development, or internal investment—maximizing strategic and financial return.

04

Execute on Strategy: Monetize or Advance

Beyond analysis, we support execution—providing buy- or sell-side advisory to help you monetize the asset or advance it through partnerships, co-development, or internal investment—maximizing strategic and financial return.